This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    ADVL1221
Previous Study | Return to List | Next Study

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01614795
First received: June 6, 2012
Last updated: November 1, 2016
Last verified: November 2016
Results First Received: March 19, 2015  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Childhood Alveolar Soft-part Sarcoma
Childhood Angiosarcoma
Childhood Epithelioid Sarcoma
Childhood Fibrosarcoma
Childhood Gliosarcoma
Childhood Leiomyosarcoma
Childhood Liposarcoma
Childhood Neurofibrosarcoma
Childhood Synovial Sarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Childhood Soft Tissue Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Osteosarcoma
Interventions: Biological: cixutumumab
Drug: temsirolimus
Other: laboratory biomarker analysis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Group 1 Relapsed or Refractory Osteosarcoma

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Group 2 Relapsed or Refractory Ewing Sarcoma/Peripheral PNET

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Group 3 Relapsed or Refractory Rhabdomyosarcoma

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Group 4 Relapsed or Refractory Non-rhabdo Soft Tissue Sarcoma

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies


Participant Flow:   Overall Study
    Group 1 Relapsed or Refractory Osteosarcoma   Group 2 Relapsed or Refractory Ewing Sarcoma/Peripheral PNET   Group 3 Relapsed or Refractory Rhabdomyosarcoma   Group 4 Relapsed or Refractory Non-rhabdo Soft Tissue Sarcoma
STARTED   11   12   11   12 
COMPLETED   0   0   0   0 
NOT COMPLETED   11   12   11   12 
Adverse Event                0                0                1                1 
Lack of Efficacy                10                10                9                8 
Physician Decision                1                0                1                1 
Withdrawal by Subject                0                1                0                2 
Ineligible                0                1                0                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Group 1 Relapsed or Refractory Osteosarcoma

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Group 2 Relapsed or Refractory Ewing Sarcoma/Peripheral PNET

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Group 3 Relapsed or Refractory Rhabdomyosarcoma

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Group 4 Relapsed or Refractory Non-rhabdo Soft Tissue Sarcoma

Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.

cixutumumab: Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).

temsirolimus: Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.

laboratory biomarker analysis: Correlative studies

Total Total of all reporting groups

Baseline Measures
   Group 1 Relapsed or Refractory Osteosarcoma   Group 2 Relapsed or Refractory Ewing Sarcoma/Peripheral PNET   Group 3 Relapsed or Refractory Rhabdomyosarcoma   Group 4 Relapsed or Refractory Non-rhabdo Soft Tissue Sarcoma   Total 
Overall Participants Analyzed 
[Units: Participants]
 11   12   11   12   46 
Age 
[Units: Participants]
Count of Participants
         
<=18 years      7  63.6%      8  66.7%      9  81.8%      7  58.3%      31  67.4% 
Between 18 and 65 years      4  36.4%      4  33.3%      2  18.2%      5  41.7%      15  32.6% 
>=65 years      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Median (Full Range)
 18 
 (7 to 25) 
 17.5 
 (9 to 27) 
 14 
 (1 to 23) 
 17.5 
 (13 to 26) 
 17 
 (1 to 27) 
Gender 
[Units: Participants]
Count of Participants
         
Female      1   9.1%      6  50.0%      8  72.7%      5  41.7%      20  43.5% 
Male      10  90.9%      6  50.0%      3  27.3%      7  58.3%      26  56.5% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
         
Hispanic or Latino      1   9.1%      0   0.0%      3  27.3%      0   0.0%      4   8.7% 
Not Hispanic or Latino      10  90.9%      12 100.0%      8  72.7%      11  91.7%      41  89.1% 
Unknown or Not Reported      0   0.0%      0   0.0%      0   0.0%      1   8.3%      1   2.2% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
         
American Indian or Alaska Native      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Asian      1   9.1%      1   8.3%      0   0.0%      2  16.7%      4   8.7% 
Native Hawaiian or Other Pacific Islander      0   0.0%      2  16.7%      0   0.0%      0   0.0%      2   4.3% 
Black or African American      2  18.2%      0   0.0%      0   0.0%      1   8.3%      3   6.5% 
White      7  63.6%      8  66.7%      9  81.8%      7  58.3%      31  67.4% 
More than one race      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Unknown or Not Reported      1   9.1%      1   8.3%      2  18.2%      2  16.7%      6  13.0% 
Region of Enrollment 
[Units: Participants]
         
United States   11   11   11   12   45 
Canada   0   1   0   0   1 


  Outcome Measures

1.  Primary:   Objective Response Rate (PR or CR) by Response Evaluation Criteria in Solid Tumors (RECIST).   [ Time Frame: 6 cycles (168 days) ]

2.  Secondary:   Progression-free Survival   [ Time Frame: The date of enrollment until the end PFI date, calculated as the date of disease progression, date of death, date of removal of all tumor by surgery or last patient contact, whichever occurs first, assessed up to 5 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   Percentage of Patients Expressing IGF-1R, Insulin Receptor, ERK, RON, and mTOR   [ Time Frame: Up to 5 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   Percentage of Patients With Detectable Bone Marrow Micrometastatic Disease Estimated as the Proportion of Eligible Patients Entered Into the Ewing Sarcoma Stratum Who Have Detectable Tumor Cells in the Marrow at Enrollment   [ Time Frame: Baseline ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

5.  Secondary:   Observed Incidence in Each Reporting Period by Type and Grade of Toxicity as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0   [ Time Frame: 25 cycles (700 days) ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Results Reporting Coordinator
Organization: Children's Oncology Group
phone: 626-447-0064
e-mail: resultsreportingcoordinator@childrensoncologygroup.org



Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01614795     History of Changes
Other Study ID Numbers: NCI-2012-01971
NCI-2012-01971 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
COG-ADVL1221 ( Other Identifier: Children's Oncology Group )
CDR0000734871 ( Other Identifier: clinical trials.gov )
ADVL1221 ( Other Identifier: Children's Oncology Group )
ADVL1221 ( Other Identifier: CTEP )
U10CA098543 ( US NIH Grant/Contract Award Number )
Study First Received: June 6, 2012
Results First Received: March 19, 2015
Last Updated: November 1, 2016